期刊
PSYCHIATRY RESEARCH
卷 175, 期 1-2, 页码 179-180出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2009.01.025
关键词
Schizophrenia; Sensory gating; Varenicline
类别
资金
- [VISN19/MIRECC]
- [RO1 MH50787-08.]
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050787] Funding Source: NIH RePORTER
Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating. Published by Elsevier Ireland Ltd
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据